Can a lupus drug help when given early?

NCT ID NCT03543839

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the drug belimumab (Benlysta) in 30 people who were diagnosed with lupus within the last two years. Participants will receive either the drug or a placebo for one year, and then some may switch to placebo in the second year. The goal is to see if early treatment can control the disease and change how the immune system behaves.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belimumab (Benlysta)
What this could lead to
If it works, this could point toward a treatment that controls lupus early on, potentially reducing long-term damage.
What could go wrong
This is a small pilot trial with only 30 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects like infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Feinstein Institute

    RECRUITING

    Manhasset, New York, 11030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.